Anyone buying AbbVie stock directly takes on its company-specific risks alone. Simply Wall St notes that AbbVie carries a high level of debt and that its dividend of 2.55% is not well covered by earnings. Owning AbbVie through a fund that also holds other healthcare businesses spreads out how much those issues can influence your overall portfolio, and also limits how much AbbVie’s individual performance can drive your results.
A recent development is news on 19 November 2026 that AbbVie is teaming up with DISCO Pharmaceuticals to work on new bispecific drugs for solid tumors. The deal brings an upfront payment to DISCO and gives AbbVie another path to cancer treatments, which could be relevant for its long-term oncology mix. Investors who want AbbVie within a broader basket can consider funds such as XLV, VHT and HDV as ways to gain that exposure.
| Fund | AbbVie weight | Rank in fund by weight | 5-year annualised return after fees | Fee | Assets |
|---|---|---|---|---|---|
| State Street Health Care Select Sector SPDR ETF (XLV) | 7.64% | #3 of 64 | 8.2% | 0.08% | US$50.57 billion |
| Vanguard Health Care ETF (VHT) | 6.73% | #3 of 417 | 7.2% | 0.09% | US$23.70 billion |
| iShares Core High Dividend ETF (HDV) | 6.91% | #2 of 80 | 12.8% | 0.08% | US$16.62 billion |
Rather choose individual stocks than a fund? Explore 35 high quality undervalued stocks.
XLV is built around large health stocks, with pharmaceuticals at 37.2% and biotechnology at 19.9% of the portfolio. Health care equipment, tools and services, managed care and distributors make up most of the rest. AbbVie is the third largest position at 7.64%, so about US$76 of every US$1,000 you put into XLV goes into AbbVie. The two bigger holdings are Eli Lilly and Johnson & Johnson, which together account for about 26.8% of the fund and have a significant influence on overall results.
AbbVie’s high level of debt is specific to its own balance sheet. XLV partly softens that single company risk because other holdings such as Eli Lilly and Johnson & Johnson rely on their own capital structures, product ranges and cash flows, not AbbVie’s. Sector concentration is the main drawback, because you still depend on how large health care stocks as a group respond to regulation, pricing pressure and sentiment toward the industry.
Not every stock inside XLV is priced the same way. Find out how many of XLV's holdings look undervalued.
Life sciences tools and services play a bigger role in VHT than in XLV, with meaningful exposure to equipment makers and research providers alongside large drugmakers. The ETF still closely resembles XLV overall, since about 87% of its holdings overlap, and Eli Lilly and Johnson & Johnson together make up just over one fifth of the fund. AbbVie is the third largest position at 6.73%, so roughly US$67 of every US$1,000 invested in VHT is tied to AbbVie rather than its peers.
Negative shareholders equity at AbbVie would be a company-level balance sheet issue. VHT can limit how much that single risk affects an investor’s money because it spreads the rest of the capital across hundreds of other health businesses, including firms focused on equipment, tools and managed care that respond more to procedure volumes and insurance trends than AbbVie’s own finances.
Uncover whether VHT has kept pace with the market over the past week, year and five years
HDV gives AbbVie real weight without letting it dominate your money. AbbVie is about 6.91% of the portfolio, so each US$1,000 puts roughly US$69 into the stock, and the rest into other high dividend companies. ExxonMobil Holdings is the largest position, and together with AbbVie makes up 15.8% of the fund. Beyond those two, the ETF leans on Integrated Oil and Gas, Tobacco, Soft Drinks and Non-alcoholic Beverages, Electric Utilities and other sectors. This creates exposure that stretches well beyond health care.
AbbVie’s dividend of 2.55% is not well covered by earnings, which leaves income investors exposed if the payout ever has to be reset. HDV partly cushions that specific weakness by owning other cash generating sectors such as Integrated Oil and Gas and Household Products that rely on their own demand and pricing. Future dividend policies across the portfolio still depend on how each underlying business performs and what its board decides.
See what you'd actually own if you bought HDV, from its 80 positions to how much sits in the top 10.
You are really picking what you want around AbbVie, not between tiny or massive stakes. XLV and HDV each put just under US$80 of every US$1,000 into AbbVie, with VHT closer to US$70, and all three charge about US$8 to US$9 a year on a US$10,000 holding. XLV and VHT cluster around large health businesses, and VHT spreads your money across far more holdings than XLV. HDV mixes AbbVie with energy, consumer and telecom stocks, so your risk is less tied to health care regulation. Recent cancer drug work with DISCO sits inside all of that. The real question is simple: do you want AbbVie mainly alongside health stocks, or as part of a wider income portfolio?
Eli Lilly is the largest holding in both XLV and VHT, so you'd own it either way. Check whether Eli Lilly trades above or below its fair value.
Fund data as of 31 October 2026. Portfolio holdings as of 31 October 2026.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com